retatrutide clinical trials safety efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Lilly's triple agonist, retatrutide, delivered

Patients should discuss potential benefits, risks, and side effects with their healthcare provider before and during treatment

It can only be accessed within authorised clinical trials

Resources on how to store peptides after reconstitution and how long peptides last in the fridge are relevant for anyone working with either compound in a research setting

Without an official SmPC, no confirmed refrigerated shelf-life or in-use storage period can be stated

Monitor closely: Weight, appetite, sideeffects, and bloodwork

Preclinical studies with GLP-1 agonists have raised questions about thyroid C-cell tumours in rodents, though this has not been confirmed in humans